Abstract Congenital dyserythropoietic anemias are a rare group of inherited anemias characterized by ineffective erythropoiesis and distinct morphological abnormalities in the erythroblasts. Interferon alpha has been shown to be effective in type 1 congenital dyserythropoietic anemia but the optimal duration of therapy is undefined. We present here a 32-years-old female patient diagnosed with type 1 congenital dyserythropoietic anemia precipitated by pregnancy and treated successfully with a short course of interferon alpha resulting in a durable response. A literature search including PubMed database on previously published articles regarding congenital dyserythropoietic anemia type 1 patients treated with interferon is conducted.
Introduction
Congenital dyserythropoietic anemias (CDAs) are a highly heterogeneous group of rare, hereditary anemias characterized by abnormalities during late erythropoiesis leading to refractory anemia, reticulocytopenia, hypercellular bone marrow with ineffective erythropoiesis, distinctive dysplastic changes in the erythroblasts and development of secondary hemochromatosis. Table 1 summarizes the characteristic features of the three major types of congenital dyserythropoietic anemias. The diagnosis of CDA relies on hematologic findings and can be confirmed by molecular testing in an increasing number of patients [1, 2] . The correct diagnosis is often delayed leading to ineffective treatments and tissue damage related to iron overload. Interferon alpha (IFN-a) is known to be effective in CDA type 1 but data are sparse and the optimal duration of therapy is a pending issue. We report here a further patient with CDA-1 and a good response to IFN and analyze previously reported CDA-1 patients treated with IFN.
Case Report
In April 2013 32-years-old female patient was referred to the hospital with severe anemia, jaundice and splenomegaly. Severe anemia was first recognized in January 2013 at the 8th month of pregnancy (hemoglobin: 4.5 g/dl During follow-up the fever resolved. Infectious causes such as brucellosis, malaria, leishmaniasis, human immunodeficiency virus, cytomegalovirus, parvovirus and Epstearr virus infections were excluded with specific laboratory tests.
Wilson's disease was also excluded (no Kaiser-Fleischer ring, normal serum copper and seruloplasmin levels and normal liver biopsy results).
Peripheral blood film revealed macrocytic red blood cells with aniso-poikilocytosis and basophilic stippling ( Fig. 1 ).
Bone marrow was hypercellular with erythroid hyperplasia (myeloid/erythroid ratio of 0.13). There was notable megaloblastic development of erythroid precursors and dyserythropoiesis. Inter-nuclear chromatin bridges involving polychromatic erythroblasts were prominent ( Fig. 2) . At least 500 nucleated erythroblasts were examined and binucleated erythroblasts were less than 5 %. An iron stain of the bone marrow aspirate identified the presence of abundant storage iron and ringed sideroblasts (\15 %). Myeloid and megakaryocytic lineages were unremarkable with a lack of atypical bone marrow cells. Grade 1 reticulin fibrosis was seen. Flow cytometric analysis of the bone marrow aspirate was nondiagnostic. Conventional cytogenetic studies on the marrow aspirate showed a normal female karyotype. Ultrastructural erythroid features included spongy (Swiss-cheese) heterochromatin (Fig. 3) .
Other causes of dyserythropoiesis were ruled out. Red cell enzyme, membrane disorders and thalassemias were excluded. G6PD and pyruvate kinase screening were normal. Hemoglobin electrophoresis showed HbA at 97.5 %, HbA 2 at 2.4 % and HbF at 0.1 %. Osmotic fragility, sucrose lysis, acidified serum lysis (Ham's test) tests and FLAER-based assays were unremarkable. Paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome and erythroleukemia were excluded. Hereditary or acquired sideroblastic anemias were excluded because sideroblasts were not prominent and acquired causes such as myelodysplastic syndromes, pyridoxine deficiency, lead poisoning and copper deficiency were ruled out. Olanzapine and sertraline are not known to produce sideroblastic anemia. A trial of pyridoxine was ineffective. Table 2 summarizes common causes of ineffective erythropoiesis and tests used to exclude them.
Codanin-1 sequencing results did not show any mutation. Liver biopsy performed to exclude Wilson's disease was consistent with extramedullary hematopoiesis. Findings of ineffective erythropoiesis, morphologically abnormal typical bone marrow erythroid precursors and exclusion of other causes of dyserythropoiesis although genetically not confirmed suggested the diagnosis of congenital dyserythropoietic anemia type 1. IFN-a 3 million units thrice weekly and deferasirox for iron chelation were initiated. After 2 weeks hemoglobin level raised to 8.2 g/ dl. In September, after 3 months of therapy she had a hemoglobin of 11.5 g/dl. She did not experience any serious side effect. Hospitalization in the psychiatry clinic was necessary because of the previously diagnosed bipolar disease attack and IFN therapy was stopped after 4 months. The patient has mild anemia without any transfusion more than 1 year after cessation of IFN.
Discussion
Congenital dyserythropoietic anemia is a diagnosis of exclusion [3, 4] . Symptoms of CDA may first appear at any time between the neonatal period and late adulthood. The diagnosis can be made in episodes of erythropoietic stress such as pregnancy [4, 5] . The patient described here presented with severe anemia during pregnancy without having an episode of anemia before.
The patient had an uncle with Wilson's disease, a diagnosis which must be considered in patients presenting with a Coombs-negative hemolytic episode and a history of neuropsychiatric disease [6] . Normal ceruloplasmin level, urinary copper excretion and absence of Kayser-Fleischer rings excluded diagnosis of Wilson's disease. The liver biopsy showed findings of extramedullary hematopoiesis within the sinusoids, probably accompanying CDA. Neurological and psychiatric evaluation indicated a psychotic depression.
Presence of ringed sideroblasts in the bone marrow in CDA is a rare finding [7] [8] [9] . Absence of hypochromia and microcytosis, unresponsiveness to pyridoxine treatment, normal serum zinc level, exclusion of myelodysplastic syndromes, lead toxicity and copper deficiency made inherited or acquired sideroblastic anemia unlikely in our patient. Light and electron microscopy findings of the bone marrow erythroblasts, the gold standard for CDA type 1 determination [4] were consistent with the diagnosis. The causative gene mutation for CDA type 1 (Codanin-1 mutation) was described first in 2002 [10] . So far, approximately 30 CDAN1 mutations have been reported in CDA type 1 patients. However no pathogenic CDAN1 mutations have been detected in 20 % of patients [11] . Although the case described above had the classic features of CDA-1, we failed to identify any mutation. This can be explained by the genetic heterogeneity of the disease.
CDA-1 patients are at high risk for complications regarding the pregnancy and delivery [5] . The patient underwent an elective cesarean section at term and the baby was born healthy. Treatment of CDAs is mostly supportive and includes erythrocyte transfusions and iron chelation. Splenectomy can increase hemoglobin levels and eliminate the need for transfusions in CDA type 2 patients without having a beneficial effect on iron overload [4, 12] . Hematopoieitic stem cell transplantation is the only available curative treatment modality and can be considered in transfusion dependent, severe patients with human leukocyte antigenidentical donors [13] .
CDA-1 patients treated with IFN have been reported so far [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] but data remained sparse. IFN treatment was started with the intention to increase hemoglobin level in our patient. Although most of the CDA-1 patients responded well to IFN therapy, patients having no favorable effect had also been reported [22] . Stopping IFN therapy in responding patients resulted in a drop in hemoglobin levels and optimal dose and duration of IFN treatment (life-long continuous or intermittent) is undefined. Table 3 summarizes information on previously published CDA-1 patients treated with IFN and the present patient. Our patient is unique in that response to IFN therapy emerged immediately and was durable after cessation of a short course of therapy. After a period of regular transfusion for 6 months, following a short course of IFN therapy (4 months) the patient is followed up without any treatment with Hb levels of 11-12 g/dl for 22 months. The apparent response to IFN treatment further supported the diagnosis of CDA type 1.
